Merck’s IBD drug hits main and key secondary goals in late-stage trial
The trial outcome de-risks Merck’s inflammatory bowel disease pipeline and changes how investors score next-regulatory steps.
By Mohammed Al-Shehri·· 3 min
1 briefing · “late-stage”
The trial outcome de-risks Merck’s inflammatory bowel disease pipeline and changes how investors score next-regulatory steps.